Subscribe To
Radiation therapy market projected to reach usd 10.6 billion, capturing a cagr of 5.4% by 2031 – report by transparency market research
A number of developments in radiation treatment, including flash therapy, image-guided therapy, synthetic CT from MRI, and ...
September 6, 2023, 11:12 am
Nanobiotix: at a crucial juncture for data
Nanobiotix is an oncology-focused biotech aiming for its first drug approval, with a tripled value since the beginning of 2023. Their flagship molecul...
August 24, 2023, 8:40 am
Galera therapeutics shares plummet after fda rejects drug for cancer treatment side effect
Galera Therapeutics shares plunged by almost 85% after the clinical-stage biopharmaceutical company revealed its New Drug Application for its investig...
August 10, 2023, 1:04 pm
Galera shares tank after us fda declines to approve inflammation disease drug
Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy...
August 9, 2023, 7:00 pm
High-dose radiotherapy systems market set to skyrocket, projected to reach us$ 4 billion by 2033, persistence market research
Rising Cases of Cancer Globally Leading to Higher Need for High-dose radiotherapy Systems: Persistence ...
July 21, 2023, 11:10 am
Galera presents additional chronic kidney disease data from roman trial at 2023 asco annual meeting
As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data d...
June 5, 2023, 6:15 pm
Galera to present one-year reductions in cisplatin-related chronic kidney disease data from roman trial at 2023 american society of clinical oncology (asco) annual meeting
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on deve...
April 26, 2023, 2:00 pm
Predictive oncology and cvergenx partner up to develop first-ever genomics-based ai approach to personalized radiation therapy and drug discovery
Predictive Oncology Inc. (NASDAQ:POAI) and Cvergenx Inc forged an agreement to form a strategic partnership that has the potential to revolutionize th...
February 23, 2023, 9:22 am
Point biopharma: interesting, novel radiotherapy developer
POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus....
February 13, 2023, 1:49 pm
Clovis (clvs) up 19.4% on upbeat data from solid tumor study
Clovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical utility of FAP-2286, its targeted ...
June 16, 2022, 5:43 pm
Clovis shares jumps after highlighting data from targeted radiotherapy trial
Clovis Oncology Inc (NASDAQ: CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labele...
June 15, 2022, 7:56 am
Astrazeneca's imfinzi fails to meet primary endpoint in phase 3 cervical cancer trial
AstraZeneca PLC (LSE:AZN) said an advanced-stage study of its Imfinzi drug failed to meets its target of improving survival in patients with cervical ...
March 24, 2022, 5:23 am
Is galera therapeutics stock a buy, sell, or hold? several catalysts to watch in 2022
Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and impr...
March 23, 2022, 11:40 am